GSK has awarded a four-year contract to Medable to enable decentralised clinical trials (DCTs) and hybrid trials across the company’s global portfolio.

For these DCTs, GSK selected Medable’s end-to-end DCT platform that provides several digital capabilities including TeleVisit, eConsent, and eCOA.

The platform also provides the flexibility to implement advanced, patient-centric trials.

Under the enterprise contract with GSK, Medable will expedite the delivery of new therapies and aid in making the company’s trials more inclusive and representative of all patient populations.

Following a thorough assessment of top clinical trial platforms, Medable’s technology was selected because it best supports the goals of GSK for boosting access to research, diversity, and making trial designs that are more patient centred.

Over 300 decentralised and hybrid trials in 60 countries have deployed the software-as-a-service platform of Medable to serve more than a million patients and research subjects across the globe.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company’s customers have attained good results with decentralised and hybrid trials, including 200% quicker subject enrolment and 50% lower expenses.

Medable co-founder and CEO Dr Michelle Longmire said: “It is an honour to be selected by GSK as its preferred partner for decentralised clinical trials.

“GSK has been a leader in innovative science for decades and is taking yet another transformational step forward by leveraging a modern, patient-centric model to conduct clinical trials with Medable.

“It’s incredibly exciting, and we are looking forward to helping millions of patients together.”

In February this year, the company introduced the Medable Partner Network, merging a varied ecosystem of technology, service, data, sites, and direct-to-patient partners that collaborate to accelerate the deployment of DCTs.